These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 33125834)

  • 1. Duration of antiretroviral therapy among people living with HIV and incidence of hypertension in Ghana.
    Sarfo FS; Singh A; Tagge R; Mensah G; Ovbiagele B
    J Clin Hypertens (Greenwich); 2020 Dec; 22(12):2361-2371. PubMed ID: 33125834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and incidence of pre-diabetes and diabetes mellitus among people living with HIV in Ghana: Evidence from the EVERLAST Study.
    Sarfo FS; Norman B; Nichols M; Appiah L; Osei Assibey S; Tagge R; Ovbiagele B
    HIV Med; 2021 Apr; 22(4):231-243. PubMed ID: 33174302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of hypertension among people living with HIV in Ghana: Impact of new hypertension guideline.
    Sarfo FS; Nichols M; Singh A; Hardy Y; Norman B; Mensah G; Tagge R; Jenkins C; Ovbiagele B
    J Clin Hypertens (Greenwich); 2019 Jun; 21(6):838-850. PubMed ID: 31125188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with incidence of stroke and heart failure among people living with HIV in Ghana: Evaluating Vascular Event Risk while on Long-Term Antiretroviral Suppressive Therapy (EVERLAST) Study.
    Sarfo FS; Norman B; Appiah L; Ovbiagele B
    J Clin Hypertens (Greenwich); 2021 Jun; 23(6):1252-1259. PubMed ID: 33939257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary trends in HIV-associated neurocognitive disorders in Ghana.
    Sarfo FS; Kyem G; Asibey SO; Tagge R; Ovbiagele B
    Clin Neurol Neurosurg; 2021 Nov; 210():107003. PubMed ID: 34715557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burden of subclinical carotid atherosclerosis and vascular risk factors among people living with HIV in Ghana.
    Sarfo FS; Nichols M; Agyei B; Singh A; Ennin E; Nyantakyi AD; Asibey SO; Tagge R; Gebregziabher M; Jenkins C; Ovbiagele B
    J Neurol Sci; 2019 Feb; 397():103-111. PubMed ID: 30599299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of hypertension among persons living with HIV in China: a multicenter cohort study.
    Fan H; Guo F; Hsieh E; Chen WT; Lv W; Han Y; Xie J; Li Y; Song X; Li T
    BMC Public Health; 2020 Jun; 20(1):834. PubMed ID: 32487185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of clinical and therapeutic factors with incident dyslipidemia in a cohort of human immunodeficiency virus-infected and non-infected adults: 1994-2011.
    Tripathi A; Jerrell JM; Liese AD; Zhang J; Rizvi AA; Albrecht H; Duffus WA
    Metab Syndr Relat Disord; 2013 Dec; 11(6):417-26. PubMed ID: 23909647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic comorbidities in persons living with HIV within three years of exposure to antiretroviral therapy at Pantang Antiretroviral Center in Ghana: a retrospective study.
    Kotey M; Alhassan Y; Adomako J; Nunoo-Mensah G; Kapadia F; Sarfo B
    Pan Afr Med J; 2022; 42():294. PubMed ID: 36415339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
    ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
    Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and risk factors for hypertension among HIV patients in rural Tanzania - A prospective cohort study.
    Rodríguez-Arbolí E; Mwamelo K; Kalinjuma AV; Furrer H; Hatz C; Tanner M; Battegay M; Letang E;
    PLoS One; 2017; 12(3):e0172089. PubMed ID: 28273105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies.
    Cancer Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord
    Clin Infect Dis; 2016 Nov; 63(10):1373-1379. PubMed ID: 27535953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment.
    Capeau J; Bouteloup V; Katlama C; Bastard JP; Guiyedi V; Salmon-Ceron D; Protopopescu C; Leport C; Raffi F; Chêne G;
    AIDS; 2012 Jan; 26(3):303-14. PubMed ID: 22089377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in Canada.
    Samji H; Taha TE; Moore D; Burchell AN; Cescon A; Cooper C; Raboud JM; Klein MB; Loutfy MR; Machouf N; Tsoukas CM; Montaner JS; Hogg RS;
    HIV Med; 2015 Feb; 16(2):76-87. PubMed ID: 25174373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and predictors of first line antiretroviral regimen modification in western Kenya.
    Inzaule S; Otieno J; Kalyango J; Nafisa L; Kabugo C; Nalusiba J; Kwaro D; Zeh C; Karamagi C
    PLoS One; 2014; 9(4):e93106. PubMed ID: 24695108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation markers and the risk of hypertension in people living with HIV.
    Ou-Yang H; Fu HY; Luo Y; Xu ZY; Liu J; Gao R; Duan JY; Mao YC; Li HJ; Du YR
    Front Immunol; 2023; 14():1133640. PubMed ID: 37025998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and risk factors of herpes zoster in human immunodeficiency virus-positive patients initiating combination antiretroviral therapy in Taiwan.
    Lee YC; Hung CC; Tsai MS; Zhang JY; Wu PY; Yang SP; Luo YZ; Chang HY; Liu WC; Sun HY; Chang SC
    J Microbiol Immunol Infect; 2018 Feb; 51(1):38-44. PubMed ID: 27329131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy.
    Rossi C; Raboud J; Walmsley S; Cooper C; Antoniou T; Burchell AN; Hull M; Chia J; Hogg RS; Moodie EE; Klein MB;
    BMC Infect Dis; 2017 Apr; 17(1):246. PubMed ID: 28376824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.
    Kowalska JD; Reekie J; Mocroft A; Reiss P; Ledergerber B; Gatell J; d'Arminio Monforte A; Phillips A; Lundgren JD; Kirk O;
    AIDS; 2012 Jan; 26(3):315-23. PubMed ID: 22112597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does region of origin influence the timing and outcome of first-line antiretroviral therapy in France?
    Gatey C; Brun A; Hamet G; Diamantis S; Sellier P; Bouchaud O; Garrait V; Rozenbaum W; Molina JM; Abgrall S;
    HIV Med; 2019 Feb; 20(2):175-181. PubMed ID: 30506853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.